Diabetes Mellitus, Type 2
Conditions
Brief summary
This study aims to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be divided into 4 groups of 20 each. * Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The biochemical parameters will be evaluated before and after the intervention.
Detailed description
This is a randomized, parallel group, open label study to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be randomly assigned to 4 groups of 20 each as follows: * Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The subjects will also be advised to be on a normal routine diet, not to skip any meal and not to change their exercise pattern (if any) during the study period.The compliance of the intervention will be monitored by instructing the patients to return all unused tablets at the end of the 8 weeks period of study. All the subjects will be asked to report after an overnight fasting of 12 hours on two occasions i.e. at the start of the study before allocation of group and 8 weeks after allocation. After measurement of body weight, height and blood pressure (by Mercury Sphygmomanometer), 5 milliliter of early morning fasting venous blood sample will be collected under aseptic measures on both the occasions. The samples collected will then be appropriately processed for the analysis of various biochemical parameters. The results of all the parameters evaluated will be recorded in the subject's Data Collection Form.The data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 21.
Interventions
DIETARY_SUPPLEMENTFolic acid
tab. Folic acid 5 mg
DIETARY_SUPPLEMENTVitamin B12
tab. Vitamin B12 500 mcg
DRUGOral hypoglycemic agents [Metformin +/- Sulfonylurea]
Patients receiving either of the following oral hypoglycemic agents 1. Sulfonylurea 2. Metformin 3. Metformin plus Sulfonylurea
Sponsors
All India Institute of Medical Sciences, Bhubaneswar
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 Diabetic patients within age group 30-65 years, on stable dose of anti-diabetic with/without anti-hypertensive drugs will be included in this study
Exclusion criteria
* Subjects on non-allopathic forms of treatment for diabetic control. * Subjects with Chronic Renal disease and Liver disease. * Subjects with malabsorption. * Subjects with Thyroid function abnormalities. * HbA1c levels more than 10 % * Smoking * Alcoholism * Pregnant subjects * Subjects with vitamin B12 deficiency * Subjects already on Folate or Vitamin B12 supplementation due to some other medical condition * The detailed drug history of the subjects will be taken prior to including them in the study. Antibiotics like Fluoroquinolones; anti-seizure drugs like phenytoin; Corticosteroids and Hormonal Contraceptives; Hypolipidemic drugs like statins are known to affect Glucose metabolism and subjects on these medications will not be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | 8 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Very Low-density lipoprotein (VLDL) | 8 weeks | — |
| Serum Homocysteine | 8 weeks | — |
| Serum Adiponectin | 8 weeks | — |
| Serum Tumor Necrosis Factor (TNF) | 8 weeks | — |
| Serum Interleukin-6 (IL-6) | 8 weeks | — |
| Serum C reactive protein (CRP) | 8 weeks | — |
| Serum High-density lipoprotein (HDL) | 8 weeks | — |
| Serum total cholesterol | 8 weeks | — |
| Fasting plasma glucose | 8 weeks | — |
| Fasting plasma insulin | 8 weeks | — |
| Serum triacylglycerol | 8 weeks | — |
| Serum Low-density lipoprotein (LDL) | 8 weeks | — |
| Insulin Resistance | 8 weeks | Using Homeostatic model assessment (HOMA2 calculator which uses fasting plasma glucose and plasma insulin values to calculate insulin resistance) |
Countries
India
Outcome results
None listed